CTOs on the Move

GlaxoSmithKline

www.gsk.com

 
We are a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. As one of the few healthcare companies researching both medicines and vaccines for the World Health Organization`s three priority diseases – HIV/AIDS, tuberculosis and malaria, we are very proud to have developed some of the leading global medicines in these fields. Our product portfolio also includes a range of consumer brands, many of which are household names around the world, including Sensodyne, Aquafresh, Horlicks, Panadol and Tums.
  • Number of Employees: 50K-100K
  • Annual Revenue: > $1 Billion
  • www.gsk.com
  • 5 Crescent Drive
    Philadelphia, PA USA 19112
  • Phone: 215.751.7160

Executives

Name Title Contact Details
Delfim Martins
VP Cyber Defense Profile
Lisa Ackerman
Deputy CISO, Cyber Security Strategy and Solutions Profile
Jeff Wrona
Senior Director, Security Infrastructure, Global Security Operations, GSK Profile
Tara Jaques
Sr. Director, Security Posture and Assurance Profile
Jon Frampton
Director, Data Security Services Profile

Similar Companies

LimaCorporate

LimaCorporate is a medical device company. LimaCorporate’s product range includes Large Joint Primary and Revision implants, Extremities and Fixation solutions and dedicated Patient-Specific prostheses division.

Concentrics Research

Concentrics Research is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunic

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.

Breakthrough Behavior

Breakthrough Behavior provides applied behavior analysis (ABA) therapy, speech therapy, and psychological testing services to children and young adults with autism and other developmental disabilities.

TetraGenx

TetraGenx is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.